B-Right AI Platform

BrightHeart is a prenatal ultrasound AI company with a registered address in Paris, France. It develops software that helps clinicians detect severe congenital heart defects (CHDs) during routine fetal ultrasound, a task that depends heavily on operator skill.

The B-Right platform has two modules. B-Right Screen analyzes images and cine clips for structural markers of severe CHDs, and B-Right Views tracks protocol completion and detects standard fetal heart views live during the exam. Results appear on a cart-side tablet and in reporting software, and the platform works with major ultrasound manufacturers. Users include fetal medicine and women's imaging centers in the United States.

• B-Right Screen: AI analysis of key structural markers to flag severe congenital heart defects.
• B-Right Views: automatic tracking of exam protocol completion.
• View detection: AI recognition of standard fetal heart views during capture.
• Cart-side tablet: results display live while scanning.
• Reporting integration: summaries linked into existing reporting software.
• Web platform: detailed assessments on a standalone web interface.

Private obstetric hospitals in Vietnam can use it to standardize second-trimester fetal heart screening. Referral fetal medicine centers can apply it as a second reader. Training programs for sonographers can use view-completion feedback.

Vendor-stated results include 96% detection of major CHDs and a 47% reduction in incomplete fetal heart scans. Reading time is reported 18% faster. Both modules are FDA-cleared and CE marked, which supports adoption in regulated markets. Compatibility with major ultrasound brands avoids replacing existing machines.

Congenital heart defects are often missed in routine prenatal scans, so AI that standardizes fetal heart views is gaining regulatory clearances and OEM distribution. In Vietnam and Southeast Asia, growing private obstetric networks and sonographer variability make such tools relevant once regional approvals are in place.

Registered address in Paris (c/o Sofinnova Partners). Closed an 11 million EUR Series A in 2026-01, announced CE Mark and European launch in 2026-07, and collaborates with GE HealthCare on the Voluson Solution Store (2026-02). FDA cleared (third clearance 2025-05).